Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
GlobalData on MSN13h
Amgen’s gMG therapy cuts disease symptoms at one-year markResults from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...
Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent ...
Generalized myasthenia gravis (gMG) happens when the immune system ... protein to prevent neuromuscular damage and help relieve symptoms. First approved in 2007, the drug is already used for ...
MedPage Today on MSN6d
Myasthenia Gravis ExacerbationsGeneralized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...
Approval in Myasthenia gravis in key markets could eventually ... and continued to suffer from significant unresolved disease symptoms. These can include difficulties seeing, walking, talking ...
Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...
Credit: shutterstock / CGN089. Amgen’s Uplizna (inebilizumab-cdon) has shown sustained efficacy in a group of generalised myasthenia gravis (gMG) patients after 52 weeks in a Phase III trial. Results ...
Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback